Bioverativ Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY17 | FY16 | FY15 | |
|---|---|---|---|
| Revenue | $259.1M | $191.7M | $560.3M |
| Operating income | $447.2M | $292.4M | $98.0M |
| Net income | $69.3M | $66.7M | $108.6M |
| Total assets | $1.62B | $731.9M | — |
| Total liabilities | $720.7M | $165.7M | — |
| Equity | $897.6M | $566.2M | $384.7M |
| EPS (diluted) | — | — | — |
| Shares out. | 108.2M | 1,000 | 108.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2017- Operating margin
- 172.6%
- Net margin
- 26.7%
- Return on equity
- 7.7%
- Return on assets
- 4.3%
- Return on capital (ROCE)
- 36.4%
- Liabilities / assets
- 44.5%
- Debt / equity
- 0.80×
- Book value / share
- $8.30
- Revenue growth (YoY)
- 35.2%
- Net income growth (YoY)
- 3.9%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2017- Altman Z″ (distress)
- 5.41safe
- Accruals / assets
- −32.2%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 6 good- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Protopapas AnnaDirector | Mar 8, 2018 | D | 1,056 | — |
| Posner Brian SDirector | Mar 8, 2018 | D | 6,693 | — |
| Paglia Louis JDirector | Mar 5, 2018 | Gift | 2,000 | $0.00 |
| Harris Timothy J.R.Officer — EVP, R & D | Mar 8, 2018 | D | 838.949 | — |
| Greene JohnOfficer — EVP, CFO and Treasurer | Mar 8, 2018 | D | 5,951.011 | — |
| Duvall DianthaOfficer — Chief Accounting Officer | Mar 8, 2018 | D | 2,791 | — |
| Difabio AndreaOfficer — EVP, Chief Legal Officer | Mar 8, 2018 | D | 30,600.203 | — |
| Denner Alexander JDirector | Mar 8, 2018 | D | 5,001 | — |
| Cox JohnOfficer — Chief Executive Officer | Mar 8, 2018 | D | 185,094 | — |
| Vivaldi Coelho RogerioOfficer — EVP, Chief Global Therapeutics | Mar 8, 2018 | D | 5,758.041 | — |
| Celona LuciaOfficer — EVP, HR & Corp Commun. Officer | Mar 8, 2018 | D | 20,396.246 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 8, 2018
- Results of operationsFeb 13, 2018
- Director / officer changeFeb 6, 2018
- Entered a material agreement · Regulation FD disclosureJan 22, 2018
- Results of operationsOct 26, 2017
- Results of operationsAug 2, 2017
- Entered a material agreement · Completed an acquisition or disposition · New financial obligation · Other material eventJun 29, 2017
- Entered a material agreement · Other material eventMay 23, 2017
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AApr 10, 2018
- 15-12BMar 19, 2018
- 4PRIMARY DOCUMENTMar 8, 2018
- 4PRIMARY DOCUMENTMar 8, 2018
- 4PRIMARY DOCUMENTMar 8, 2018
- 4PRIMARY DOCUMENTMar 8, 2018
- 4PRIMARY DOCUMENTMar 8, 2018
- 4PRIMARY DOCUMENTMar 8, 2018
- 4PRIMARY DOCUMENTMar 8, 2018
- 4PRIMARY DOCUMENTMar 8, 2018
- 4PRIMARY DOCUMENTMar 8, 2018
- 4PRIMARY DOCUMENTMar 8, 2018
- 4PRIMARY DOCUMENTMar 8, 2018
- 4PRIMARY DOCUMENTMar 8, 2018
- 4PRIMARY DOCUMENTMar 8, 2018
Corporate family
Spun off from BiogenBIIB · Jan 31, 2017
From the spin-off filings we track. Follow a company to walk its own history.